Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck-Reply

Affiliations

¹ Royal Marsden Hospital/The Institute of Cancer Research NIHR Biomedical Research Centre, London, United Kingdom.
² Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Comment

Kevin J Harrington et al. JAMA Oncol. 2024.

. 2024 Jan 1;10(1):144-145.

doi: 10.1001/jamaoncol.2023.5407.

¹ Royal Marsden Hospital/The Institute of Cancer Research NIHR Biomedical Research Centre, London, United Kingdom.
² Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

No abstract available

Comment on

Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck.
Klein O. Klein O. JAMA Oncol. 2024 Jan 1;10(1):143-144. doi: 10.1001/jamaoncol.2023.5404. JAMA Oncol. 2024. PMID: 37991743 No abstract available.
Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck.
Parast L, Tian L, Wei LJ. Parast L, et al. JAMA Oncol. 2024 Jan 1;10(1):142-143. doi: 10.1001/jamaoncol.2023.5401. JAMA Oncol. 2024. PMID: 37991750 No abstract available.